Clinical trial NCT02457637: Chinese CLIF-C Acute-on-Chronic Liver Disease and Liver Failure Study
Official title: Chinese Chronic Liver Failure Consortium Acute-on-Chronic Liver Disease and Failure Study --a Prospective Multi-center Study in China, the Largest Hepatitis B Virus High-endemic Region.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Liver Failure, Acute on Chronic
Keywords: acute-on-chronic liver disease
acute decompensation
multiple organ failures
acute on chronic liver failure
Lead sponsor: Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2015-05-29
Enrollment: 2600
Sex: ALL
Minimum age (years): 15
Maximum age (years): 79
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: chronic liver disease patients（having liver dysfunction more than 6 months） with acute liver injury\[having ALT(alanine aminotransferase)\>3NL(normal level),AST(aspartate aminotransferase)\>3NL or TB(total bilirubin)\>2NL within 1 week before enrollment\] or acute decompensation\[having ascites, hepatic encephalopathy, bacterial infection ,gastrointestinal bleeding or jaundice(TB\>5NL)within 1 month before enrollment\].

Brief summary: Acute on chronic liver failure (ACLF) is a distinct entity encompassing the acute deterioration of liver function, culminating in multiple organs failure and high short-term mortality. Currently, there are differences in definitions and descriptions between western and eastern types of ACLF, especially in the definition of chronic liver disease and its precipitating events. The CANONIC (EASL-CLIF ACLF in Cirrhosis) study put forward CLIF-SOFA (chronic liver failure-sequential organ failure assessment) scores as the clinical diagnostic criteria of ACLF in 2013. Although the Asian Pacific Association for the Study of the Liver (APASL) reached a consensus for diagnostic criteria of ACLF in 2008, it is based on expert opinion. This prospective multicenter clinical trial is launched to clarify the eastern type of ACLF (HBV related) and estimate whether the eastern and western (alcoholic related) types are homogenous. 3 key points of concern are: (1) Whether HBV and non-HBV ACLFs are belonged to a homogenous disease entity which share the same diagnostic criteria, disease grades classification and prognostic model? (2) Whether acute deteriorating patients from cirrhosis or from mild fibrosis (S1-S2) belong to a homogenous entity? (3) To clarify if there are heterogenous groups in APASL criteria diagnosed ACLF patients.

14 Chinese national wide liver centers have been included. Continuous hospitalized chronic liver disease patients of various etiologies (including both cirrhotic and non-cirrhotic) with acute decompensation (AD) or acute hepatic injury (ALI) (aminotransferase \> 3NL(normal level)) will be recruited from January to December 2015. Biochemical parameters, organ failure will be collected and evaluated at day 1,4,7,14,21 and 28 after enrollment. Patients'death and LT (liver transplantation) are the primary and secondary endpoints of observation. Mortality and LT rate will be calculated at 28 days,90 days,180 days,1 year and 2 years after enrollment. Considering there will lack of liver biopsy in most of the patients, both CT and FibroScan as supplementary methods to differentiate non-cirrhotic patients. The patients will be continuously followed up once a month until the 24th month after hospital discharging and follow similar hospitalization process again whenever they have new ALI or AD. Data about the patients from stable chronic liver disease to deterioration will be acquired analyzed according to the questions hoped to resolve.

Detailed description: Acute-on chronic liver failure (ACLF) was first described by Japanese researchers in 1995. In 2011, the American Association for the Study of Liver Disease (AASLD) and the European Association for the Study of the Liver (EASL) concluded that the core characteristics of ACLF were multiple organ failures and high short-term mortality. In 2013, the EASL-CLIF (the European Association for the Study of The Liver-chronic liver failure) established the CLIF-SOFA (chronic liver failure-sequential organ failure assessment) criteria of ACLF through a prospective multicenter study at 29 liver units in eight European countries for 1 year, with a focus on patients with alcoholic cirrhosis with acute decompensation (AD). In China, patients with acute deterioration of previously chronic liver disease were diagnosed with chronic severe hepatitis, until 2008 these patients had been termed "ACLF", due to the APASL reached a consensus of diagnostic criteria of ACLF. In the Asia-Pacific region, the majority of liver disease is viral hepatitis, while in western countries, it is alcoholic liver disease. There is a sharp east-west divide with respect to the definition of ACLF, especially in the definition of chronic liver disease and its precipitating events.

The investigators analyzed 6 years' data of hepatitis B virus (HBV)-related chronic liver disease in patients with AD in two affiliated hospitals of Shanghai Jiao Tong University School of Medicine. These data were also quantified and sent to the EASL-CLIF centre for analysis. 80% of whole patients were clinically diagnosed with cirrhosis, 30% of which had pathological diagnosis. Through analysis of the liver tissues of the liver transplantation (LT) patients, 95% had pseudolobules. The residual 5% of liver tissues were in the S3 stage of progressive liver fibrosis. Compared with the CANONIC (EASL-CLIF Acute-on-Chronic Liver Failure in Cirrhosis), there are many similarities between ACLF patients with alcoholic cirrhosis or HBV induced cirrhosis: (1)The age of ACLF patients is younger than that of cirrhotic patients with AD. (2)ACLF is exist at any stage of liver fibrosis. (3)The number of organ failures decides the severity of the disease and is related to mortality of the patient. (4) Predisposition to acute liver injury (ALI) does not correlate with the history of the disease and outcome of the patient. (5)The 90-day mortality rate of ACLF is 45-50%, which is obviously higher than that of non-ACLF patients (5%). (6)Eastern and western types of ACLF can have similar SOFA scores as a diagnostic criterion (CLIF-OF or CLIF-SOFA), and a similar prognostic model to predict the outcomes of ACLF and non-ACLF patients. ACLF patients with cirrhosis induced by HBV or alcoholism differ in main types of organ failure. The former group is liver failure (total bilirubin≥12mg/dl) and coagulation failure(international normalized ratio; INR≥2.5), whereas the latter group is renal failure(creatinine≥2mg/dl or use of renal replacement therapy) and nervous system failure(hepatic encephalopathy; HE≥III grade).

Research on hepatic pathology in HBV-induced ACLF patients after LT in RenJi Hospital demonstrated that the pathological characteristics of ACLF may be MHN/SMHN (massive hepatic necrosis/submassive hepatic necrosis) in the background of liver pseudolobules. Regeneration of hepatic progenitor cells, cholestasis, and sepsis are other possible pathological features of ACLF.

It is necessary to conduct a prospective multicentre study to clarify the eastern type of ACLF and the differences between the eastern and western types of ACLF. The investigators are going to identify three key points: (1)Whether HBV and non-HBV ACLFs are belong to a homogenous disease entity which share the same diagnostic criteria, disease grades classification and prognostic model; (2) Whether acute deteriorating patients from cirrhosis or from mild fibrosis (S1-S2) belong to a homogenous entity? (3)To clarify if there are heterogenous groups in APASL criteria diagnosed ACLF patients.

The investigators plan to enroll 2000-3000 consecutive patients from January to December 2015. The research will be carried out in about 14 Chinese national wide liver centers each of whose total beds are around 500.

The research has two stages. The first stage will be enrollment of 2000-3000 consecutive patients from January to December 2015. Only chronic liver disease patients of various etiologies with AD or ALI will be enrolled. Biochemical parameters, organ failure evaluation, imaging test results treatment therapies will be recorded at day 1,4,7,14,21 and 28 (or last visit date) after enrollment according to case report form. If the patients die or undergo LT, the data at the 24h prior to death or LT will be also recorded. The second stage will be follow-up from January 2016 to December 2017. If the patients improve and are discharged, 24 months' follow-up should be conducted. Whenever the patients die or have LT, the study will be end. Follow-up will be clinical visiting, but telephone call will be acceptable for patients unable to attend. During follow-up, patients will be hospitalized again whenever they have new ALI or AD. Similar data will be collected reference to their prior admission and follow-up will restart.

Every patient will have a unique number. As soon as they are hospitalized, name, age, sex, ID(identification) number, telephone number, e-mail address, WeChat(a popular mobile phone text and voice messaging communication service) number, family address, and degree of education will be collected. The investigators will get the history and etiology of their liver disease, such as hepatitis B, alcoholic liver disease, and autoimmune liver disease. For viral hepatitis, the investigators will ask how antiviral therapy is conducted. The investigators will ascertain if the patients have a history of cirrhosis and for how long. The investigators will ascertain if the patients have any of the following predisposing factors: HBV reactivation, bacterial infection, active alcohol intake, HBV superimposed by other hepatitis viruses, gastrointestinal bleeding, portal vein thrombosis, surgery, intake of hepatotoxic drugs or herbs, or physiological exhaustion. The investigators will establish the main cause of admission: gastrointestinal bleeding, hepatic encephalopathy, ascites, bacterial infection or ALI. The investigators will determine whether the patients have chronic disease such as hypertension, coronary heart disease, diabetes, chronic renal disease, or connective tissue disease.

During hospitalization, data will be collected at 1, 4, 7,14, 21 and 28 days (or last visit date, if the patient is hospitalized less than 28 days), and 24h prior to death or LT (if the patient dies or has LT) and focus on the following three aspects.

The first aspect is evaluation of organ failure. The circulatory system will be evaluated by measuring heart rate and blood pressure and use of vasopressors. Renal function will be evaluated by serum creatinine or renal replacement therapy. Coagulation function will be evaluated by INR (international normalized ratio of prothrombin time). Liver function will be evaluated by serum total bilirubin. The respiratory system will be evaluated by the ratio of oxyhemoglobin saturation and fraction of inspired oxygen. The nervous system will be evaluated by the grade of hepatic encephalopathy. Bacterial infection, including pneumonia, urinary tract infection, spontaneous bacterial peritonitis, spontaneous bacteremia, and cellulitis will be evaluated by positive culture results or imaging findings. Systemic inflammatory reactive syndrome, sepsis, severe sepsis and septic shock will also be assessed. Gastrointestinal bleeding before and after admission, treatment with diuretics, and paracentesis will be recorded. The investigators will establish whether ascites and hepatic encephalopathy can be medically controlled.

The second aspect is laboratory examinations. Tests at admission will include routine blood, urine and stool tests, liver and renal function tests, blood electrolytes, blood-gas analysis, blood glucose, coagulation test, C-reactive protein (CRP), procalcitonin (PCT), HBV antibodies and antigens, anti-hepatitis A (IgM), HBV-DNA, anti-hepatitis E (IgM), anti-hepatitis C, and immunoglobulins (IgA, IgG, IgM and IgM-4). Tests at other times will include blood, urine and stool routine tests, liver and renal function tests, blood electrolytes, blood glucose, coagulation test, CRP and PCT (procalcitonin). Tests optionally done during hospitalization will include autoantibody measurement, blood culture(if the patients have fever and shivering), sputum culture(if there is suspicion of pulmonary infection),middle urine cultivation(when there is suspicion of urinary tract infection) and ascites culture(when there is suspicion of spontaneous bacterial peritonitis).

The third aspect is imaging. During hospitalization, thoracic X ray or computed tomography (CT) will be done to diagnose pulmonary infection. Abdominal CT (enhanced when necessary), B ultrasound and FibroScan or other elastography will be done to diagnose cirrhosis (or fibrosis), portal thrombosis, esophageal and gastric varices and hepatocellular carcinoma.

Patients will be followed up regularly after discharge. When the patients die during follow-up, the time of death and main cause of death will be noted. When the patients undergo LT during follow-up, the time of LT and the results of hepatic pathology will be noted.

Follow-up is by clinical visiting or telephone call depending on whether the patient can attend the clinic. Clinical follow-up is once a month for 2 years adding to 24 visits. The time of visit will be recorded. Antiviral therapy and alcohol intake will be monitored(if the patient has). Laboratory tests include routine blood tests, liver and renal function test, coagulation test, CRP and PCT. B ultrasound will be done to monitor cirrhosis (or fibrosis) and hepatocellular carcinoma. Telephone follow-up will be at 28 days, 3, 6,9, 12, 15, 18, 21 and 24 months. The investigators will determine whether there are new complications (e.g. gastrointestinal bleeding, hepatic encephalopathy, ascites, bacterial infection) and hepatocellular carcinoma.

Referring to the structure of the clinical research of CANONIC study, the investigators will meet every three months to exchange results and ideas. All young committee members from Chinese Society of Hepatology can campaign for joining in this research. There will be a core group with 3-4 members comprising experts with an interest in ACLF. These core members will be responsible for making policies. Members of core group are flexible. Monopolizing and arbitrariness should be forbidden.

Independent departments of gastroenterology, hepatology or infectious diseases are a requirement of the hospitals. Every hospital should have only one principal investigator (PI) as their representative. The PI should be the head of the department and involved in clinical work. The PI should make ward rounds at least twice weekly and evaluate the patients beside the bed. Young members of Chinese Society of Hepatology will be prioritized for the PI. If the young members do not undertake clinical work, they can recommend an eligible attending physician.

There are some measures to guarantee the quality of follow-up. First, set up fast-track follow-up cards for each patient. These patients have priority to make an appointment and see a doctor. Second, every PI should have their assistants. Every assistant is equipped with a cellphone so that patients can call to visit a doctor immediately or be hospitalized in an emergency. Third, set up a WeChat group for patients to inform them about follow-up 1 week in advance. Fourth, every assistant should master the follow-up strategies.

Eligibility criteria: Inclusion Criteria:

* inpatient (hospitalization \>1 days)(including patient in emergency observation wards)
* chronic liver disease patients including non-alcoholic fatty liver disease patients,chronic liver hepatitis patients without cirrhosis, compensated cirrhosis patients and decompensated cirrhosis patients
* having acute liver injury \[ALT(alanine aminotransferase)\>3NL(normal level),AST(aspartate aminotransferase)\>3NL or TB(total bilirubin)\>2NL within 1 week before enrollment\] or acute decompensation\[having ascites, hepatic encephalopathy, bacterial infection ,gastrointestinal bleeding or jaundice(TB\>5NL)within 1 month\].

Exclusion Criteria:

* pregnancy
* hepatocellular carcinoma or other liver malignancies
* malignancy of other organs
* severe chronic extrahepatic disease including chronic obstructive pulmonary disease combined with respiratory failure, coronary heart disease with cardiac function level 3 (NYHA), myocardial infarction in the 3 months before admission, diabetes with severe complications and chronic kidney disease with end-stage renal failure
* receiving immunosuppressive drugs for reasons other than chronic liver disease

Primary outcomes:
measure: 28-day Mortality,28-day Liver-transplantation Free Mortality& 28-day Liver Transplantation Rate
timeFrame: up to 28 days
Secondary outcomes:
measure: 90-day Mortality Rates, 90-day Liver Transplantation Free Mortality and Liver Transplantation Rate
timeFrame: up to 90 days
measure: 180-day Mortality Rate and Liver Transplantation Rate
timeFrame: up to 180 days
Other outcomes:
measure: The Appearance and Number of Organ Failure
timeFrame: Up to 28 days
measure: Models for Disease Severity
timeFrame: Up to 28 days
measure: Serum Bilirubin
timeFrame: Up to 28 days
Locations:
city: Beijing
country: China
facility: Ditan Hospital of integrated traditional Chinese and Western Medicine Center
state: Beijing
city: Chongqing
country: China
facility: Southwest Hospital of Third Military Medical University
state: Chongqing
city: Fuzhou
country: China
facility: Fuzhou general hospital of Xiamen university
state: Fujian
city: Guangzhou
country: China
facility: Southern hospital infection department
state: Guangdong
city: Tianjing
country: China
facility: Affiliated Hospital of the Armed Police Logistics College
state: Hebei
city: Zhengzhou
country: China
facility: Henan Provincial People's Hospital
state: Henan
city: Shiyan
country: China
facility: Taihe Hospital
state: Hubei
city: Wuhan
country: China
facility: Wuhan Union Hospital of Huazhong University of Science and Technology
state: Hubei
city: Changsha
country: China
facility: Xiangya hospital of Central South University
state: Hunan
city: Changchun
country: China
facility: The First Affiliated Hospital of Jilin University
state: Jilin
city: Jinan
country: China
facility: The Second Hospital of Shandong University
state: Shandong
city: Shanghai
country: China
facility: Fudan University Huashan hospital
state: Shanghai
city: Shanghai
country: China
facility: Fudan University Zhongshan hospital
state: Shanghai
city: Shanghai
country: China
facility: Renji hospital of Shanghai Jiao Tong University School of Medical
state: Shanghai
city: Shanghai
country: China
facility: Shanghai Public Health Clinical Center
state: Shanghai
city: Ürümqi
country: China
facility: The First Teaching Hospital of Xinjiang Medical University
state: Xinjiang
Study officials:
affiliation: RenJi Hospital
name: Hai Li
role: STUDY_DIRECTOR
References:
citation: Ohnishi H, Sugihara J, Moriwaki H, Muto Y. [Acute-on-chronic liver failure]. Ryoikibetsu Shokogun Shirizu. 1995;(7):217-9. No abstract available. Japanese.
citation: Kim TY, Kim DJ. Acute-on-chronic liver failure. Clin Mol Hepatol. 2013 Dec;19(4):349-59. doi: 10.3350/cmh.2013.19.4.349. Epub 2013 Dec 28.
citation: Olson JC, Wendon JA, Kramer DJ, Arroyo V, Jalan R, Garcia-Tsao G, Kamath PS. Intensive care of the patient with cirrhosis. Hepatology. 2011 Nov;54(5):1864-72. doi: 10.1002/hep.24622.
citation: Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASL-CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9. doi: 10.1053/j.gastro.2013.02.042. Epub 2013 Mar 6.
citation: Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Gines P, Levesque E, Durand F, Angeli P, Caraceni P, Hopf C, Alessandria C, Rodriguez E, Solis-Munoz P, Laleman W, Trebicka J, Zeuzem S, Gustot T, Mookerjee R, Elkrief L, Soriano G, Cordoba J, Morando F, Gerbes A, Agarwal B, Samuel D, Bernardi M, Arroyo V; CANONIC study investigators of the EASL-CLIF Consortium. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014 Nov;61(5):1038-47. doi: 10.1016/j.jhep.2014.06.012. Epub 2014 Jun 17.
citation: Sun QF, Ding JG, Xu DZ, Chen YP, Hong L, Ye ZY, Zheng MH, Fu RQ, Wu JG, Du QW, Chen W, Wang XF, Sheng JF. Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. J Viral Hepat. 2009 Jul;16(7):464-70. doi: 10.1111/j.1365-2893.2008.01046.x. Epub 2009 Apr 29.
citation: Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009 Sep 24;361(13):1279-90. doi: 10.1056/NEJMra0809139. No abstract available.
citation: Blei AT, Cordoba J; Practice Parameters Committee of the American College of Gastroenterology. Hepatic Encephalopathy. Am J Gastroenterol. 2001 Jul;96(7):1968-76. doi: 10.1111/j.1572-0241.2001.03964.x.
citation: Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R; United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003 Jan;124(1):91-6. doi: 10.1053/gast.2003.50016.
citation: Bajaj JS, O'Leary JG, Reddy KR, Wong F, Olson JC, Subramanian RM, Brown G, Noble NA, Thacker LR, Kamath PS; NACSELD. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology. 2012 Dec;56(6):2328-35. doi: 10.1002/hep.25947.
citation: Gu WY, Xu BY, Zheng X, Chen J, Wang XB, Huang Y, Gao YH, Meng ZJ, Qian ZP, Liu F, Lu XB, Shang J, Li H, Wang SY, Sun X, Li H. Acute-on-Chronic Liver Failure in China: Rationale for Developing a Patient Registry and Baseline Characteristics. Am J Epidemiol. 2018 Sep 1;187(9):1829-1839. doi: 10.1093/aje/kwy083.
citation: Wang T, Tan W, Wang X, Zheng X, Huang Y, Li B, Meng Z, Gao Y, Qian Z, Liu F, Lu X, Yan H, Zheng Y, Zhang W, Yin S, Gu W, Zhang Y, Dong F, Wei J, Deng G, Xiang X, Zhou Y, Hou Y, Zhang Q, Xiong S, Liu J, Long L, Chen R, Chen J, Jiang X, Luo S, Chen Y, Jiang C, Zhao J, Ji L, Mei X, Li J, Li T, Zheng R, Zhou X, Ren H, Shi Y, Li H; Chinese (Acute on) Chronic Liver Failure Consortium (Ch-CLIF.C). Role of precipitants in transition of acute decompensation to acute-on-chronic liver failure in patients with HBV-related cirrhosis. JHEP Rep. 2022 Jul 5;4(10):100529. doi: 10.1016/j.jhepr.2022.100529. eCollection 2022 Oct.
citation: Mei X, Li H, Deng G, Wang X, Zheng X, Huang Y, Chen J, Meng Z, Gao Y, Liu F, Lu X, Shi Y, Zheng Y, Yan H, Zhang W, Qiao L, Gu W, Zhang Y, Xiang X, Zhou Y, Sun S, Hou Y, Zhang Q, Xiong Y, Zou C, Chen J, Huang Z, Li B, Jiang X, Zhong G, Wang H, Chen Y, Luo S, Gao N, Liu C, Li J, Li T, Zheng R, Zhou X, Ren H, Yuan W, Qian Z. Prevalence and clinical significance of serum sodium variability in patients with acute-on-chronic liver diseases: a prospective multicenter study in China. Hepatol Int. 2022 Feb;16(1):183-194. doi: 10.1007/s12072-021-10282-8. Epub 2022 Jan 17.
citation: Sun S, Xu B, Tan W, Xiang X, Zhou Y, Dan Y, Guo Y, Tan Z, Deng G. Testosterone and Estradiol as Novel Prognostic Indicators for HBV-Related Acute-on-Chronic Liver Failure. Front Med (Lausanne). 2021 Sep 8;8:729030. doi: 10.3389/fmed.2021.729030. eCollection 2021.
citation: Ouyang R, Li H, Xia J, Wang X, Zheng X, Huang Y, Meng Z, Gao Y, Qian Z, Liu F, Lu X, Shi Y, Shang J, Liu J, Deng G, Zheng Y, Yan H, Zhang W, Qiao L, Jiang X, Wang H, Zhong G, Li B, Chen J. Lower platelet counts were associated with 90-day adverse outcomes in acute-on-chronic liver disease patients. Ann Palliat Med. 2021 Sep;10(9):9342-9353. doi: 10.21037/apm-21-1019. Epub 2021 Aug 13.
citation: Chen J, Huang ZB, Li H, Zheng X, Chen JJ, Wang XB, Qian ZP, Liu XX, Fan XG, Hu XW, Liao CJ, Long LY, Huang Y. Early Diagnostic Biomarkers of Sepsis for Patients with Acute-on-Chronic Liver Failure: A Multicenter Study. Infect Dis Ther. 2021 Mar;10(1):281-290. doi: 10.1007/s40121-020-00362-x. Epub 2020 Nov 4.
citation: Li B, Gao Y, Wang X, Qian Z, Meng Z, Huang Y, Deng G, Lu X, Liu F, Zheng X, Li H, Chen J. Clinical features and outcomes of bacterascites in cirrhotic patients: A retrospective, multicentre study. Liver Int. 2020 Jun;40(6):1447-1456. doi: 10.1111/liv.14418. Epub 2020 Mar 17.
citation: Zhang Y, Xu BY, Wang XB, Zheng X, Huang Y, Chen J, Meng ZJ, Gao YH, Qian ZP, Liu F, Lu XB, Shi Y, Shang J, Li H, Wang SY, Yin S, Sun SN, Hou YX, Xiong Y, Chen J, Li BL, Lei Q, Gao N, Ji LJ, Li J, Jie FR, Zhao RH, Liu JP, Lin TF, Chen LY, Tan WT, Zhang Q, Zou CC, Huang ZB, Jiang XH, Luo S, Liu CY, Zhang YY, Li T, Ren HT, Wang SJ, Deng GH, Xiong SE, Liu XX, Wang C, Yuan W, Gu WY, Qiao L, Wang TY, Wu DD, Dong FC, Li H, Hua J. Prevalence and Clinical Significance of Portal Vein Thrombosis in Patients With Cirrhosis and Acute Decompensation. Clin Gastroenterol Hepatol. 2020 Oct;18(11):2564-2572.e1. doi: 10.1016/j.cgh.2020.02.037. Epub 2020 Feb 25.